Format

Send to

Choose Destination
Drug Deliv Transl Res. 2018 Aug;8(4):868-882. doi: 10.1007/s13346-017-0431-2.

Monocyte-mediated drug delivery systems for the treatment of cardiovascular diseases.

Author information

1
Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, 9112001, Jerusalem, Israel.
2
Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, 9112001, Jerusalem, Israel. gershong@ekmd.huji.ac.il.

Abstract

Major advances have been achieved in understanding the mechanisms and risk factors leading to cardiovascular disorders and consequently developing new therapies. A strong inflammatory response occurs with a substantial recruitment of innate immunity cells in atherosclerosis, myocardial infarction, and restenosis. Monocytes and macrophages are key players in the healing process that ensues following injury. In the inflamed arterial wall, monocytes, and monocyte-derived macrophages have specific functions in the initiation and resolution of inflammation, principally through phagocytosis, and the release of inflammatory cytokines and reactive oxygen species. In this review, we will focus on delivery systems, mainly nanoparticles, for modulating circulating monocytes/monocyte-derived macrophages. We review the different strategies of depletion or modulation of circulating monocytes and monocyte subtypes, using polymeric nanoparticles and liposomes for the therapy of myocardial infarction and restenosis. We will further discuss the strategies of exploiting circulating monocytes for biological targeting of nanocarrier-based drug delivery systems for therapeutic and diagnostic applications.

KEYWORDS:

Drug delivery systems; Liposomes; Monocyte subpopulations; Monocytes; Polymeric nanoparticles; Vascular injury

PMID:
29058205
DOI:
10.1007/s13346-017-0431-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center